Marshfield Clinic Approved to Use New Therapy in Lung Cancer Treatment
Wednesday, November 12th, 2014 -- 8:12 AM
-Patients with lung cancer can find hope in a new, personalized approach to treatment since Marshfield Clinic has been approved to use a therapy guided by genomic profiling.Marshfield Clinic Research Foundation, working with Gundersen Health System of La Crosse and St. Vincent Cancer Center of Green Bay in a collaboration called WiNCORP, is participating in a clinical trial, called Lung-MAP, to treat squamous cell lung cancer.
Squamous cell lung cancer is a common cell type of lung cancer seen in patients who smoke. More than 200,000 cases of lung cancer are diagnosed annually in the United States, according to the most current data from Centers for Disease Control and Prevention.
Lung-MAP uses state-of-the-art genomic profiling to match patients to sub-studies testing investigational treatments that may target the genomic alterations, or mutations, found driving cancer growth.
The primary objective is to learn whether a targeted cancer therapy matched to the genomic makeup of a patient's lung cancer tumor is more effective than the current standard therapy in halting or reversing progress of the disease and in extending the patient's life.
Feel free to contact us with questions and/or comments.